A5014958682- CAR-T cell therapy research
- Virus-based gene therapy research
- Acute Lymphoblastic Leukemia research
- Lymphoma Diagnosis and Treatment
- Advancements in Semiconductor Devices and Circuit Design
- Nanowire Synthesis and Applications
- Immune Cell Function and Interaction
Institute of Hematology & Blood Diseases Hospital
2022-2024
Chinese Academy of Medical Sciences & Peking Union Medical College
2022-2024
Beijing Tongren Hospital
2022
Patients with relapsed or refractory T-cell acute lymphoblastic leukemia (r/r T-ALL) have few options and poor prognosis. The aim was to assess donor-derived anti-CD7 chimeric antigen receptor (CAR) safety efficacy in patients r/r T-ALL.In this single-center, phase I trial, we administered CAR T cells, manufactured from either previous stem-cell transplantation donors new donors, T-ALL, single infusions at doses of 5 × 105 1 106 (±30%) cells per kilogram body weight. primary end point...
Abstract Chimeric antigen receptor (CAR) T cells show suboptimal efficacy in acute myeloid leukemia (AML). We find that CAR exposed to impaired activation and cytolytic function, accompanied by downstream calcium, ZAP70, ERK, C-JUN signaling, compared those B-cell leukemia. These defects are caused part the high expression of CD155 AML. Overexpressing C-JUN, but not other components, maximally restores anti-tumor function. overexpression increases costimulatory molecules cytokines through...
7035 Background: Refractory or relapsed (r/r) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) has a poor prognosis. Our previous report showed that donor-derived CD7 CAR-T cell therapy could induce remission of r/r T-ALL, but graft-versus-host disease (GVHD) occurred in some patients (Pan et al. J Clin Oncol 2021;39:3340-3351). We recently conducted phase I trial to evaluate autologous T-ALL/LBL, which may avoid GVHD while showing the efficacy; here we early result with approval...
Abstract In recent years, CD19‐directed chimeric antigen receptor (CAR) T cell therapy has exhibited significant potency for treating pediatric relapsed or refractory B‐cell acute lymphoblastic leukemia (r/r B‐ALL). Nonetheless, many patients with disease progressing rapidly may not benefit from this therapy. Actually, 10%–20% of these progressive failed in CAR manufacturing. Besides, some died progression earlier than cells expanding vivo. How to deal the fast and ensure successful...